Structure Therapeutics’ (GPCR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $80.00 price objective on the stock.

GPCR has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley began coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and an average price target of $86.50.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $27.90 on Thursday. Structure Therapeutics has a fifty-two week low of $26.23 and a fifty-two week high of $62.74. The firm has a fifty day moving average price of $35.32 and a two-hundred day moving average price of $38.75. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -37.70 and a beta of -3.41.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of GPCR. Geode Capital Management LLC increased its holdings in Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after buying an additional 312 shares during the period. Squarepoint Ops LLC raised its position in Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock worth $567,000 after purchasing an additional 617 shares in the last quarter. Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. Sandia Investment Management LP acquired a new stake in Structure Therapeutics during the second quarter valued at approximately $39,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.